Grants to Conquer the ‘Digital Divide’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

BETHESDA, Md-The National Cancer Institute has given four awards totaling $932,000 to four existing NCI contractors to develop research to understand, and pilot programs to breach, the “Digital Divide” that prevents many members of minorities from accessing cancer information on the Internet.

BETHESDA, Md—The National Cancer Institute has given four awards totaling $932,000 to four existing NCI contractors to develop research to understand, and pilot programs to breach, the “Digital Divide” that prevents many members of minorities from accessing cancer information on the Internet.

The four awards went to contractors who operate regional information centers for NCI’s Cancer Information Service (CIS). They will cover 1 year, with the possibility of a 6-month extension.

The awardees are the CIS New York State (Memorial Sloan-Kettering Cancer Center); CIS North Central and Mid-West Regions (University of Wisconsin, Madison, and Karmanos Cancer Center, Detroit); CIS New England Region (Yale Cancer Center); and CIS Mid-South Region (Markey Cancer Cener, Kentucky, and the Louisiana State University Health Sciences Center).

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content